Iridex Partners with EyeProGPO, Expanding Retina Laser Access to 1,800+ Members
summarizeSummary
Iridex Corporation announced a new partnership with EyeProGPO, an ophthalmology-focused group purchasing organization with over 1,800 members. This agreement provides EyeProGPO members with preferred pricing and expanded access to Iridex's retina laser platforms, including PASCAL, IQ 532/577, and OcuLight TX lasers. This partnership builds on an existing relationship, as EyeProGPO already contracts for Iridex's glaucoma products. For a company of Iridex's size, securing a streamlined sales channel to over 1,800 potential customers is a significant positive development that could materially boost product adoption and revenue for its retina laser technology. Investors should monitor future financial reports for the impact of this expanded partnership on Iridex's sales growth and market penetration.
At the time of this announcement, IRIX was trading at $1.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.8M. The 52-week trading range was $0.79 to $1.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.